Sean Blakley Singer, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heterosexuality | 2 | 2020 | 309 | 1.180 |
Why?
|
| Gender Identity | 3 | 2020 | 765 | 1.030 |
Why?
|
| Isotretinoin | 3 | 2020 | 133 | 0.820 |
Why?
|
| Sunbathing | 1 | 2020 | 65 | 0.660 |
Why?
|
| Sex Reassignment Procedures | 1 | 2020 | 70 | 0.650 |
Why?
|
| Alopecia | 2 | 2020 | 411 | 0.640 |
Why?
|
| Skin Neoplasms | 5 | 2022 | 5815 | 0.630 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 2018 | 22 | 0.610 |
Why?
|
| Acne Vulgaris | 2 | 2020 | 357 | 0.600 |
Why?
|
| Cellulitis | 1 | 2019 | 209 | 0.560 |
Why?
|
| Drug Eruptions | 1 | 2019 | 335 | 0.540 |
Why?
|
| Exanthema | 1 | 2019 | 504 | 0.490 |
Why?
|
| Pemphigoid, Bullous | 3 | 2022 | 114 | 0.480 |
Why?
|
| Risk-Taking | 1 | 2020 | 1036 | 0.460 |
Why?
|
| Arthralgia | 1 | 2018 | 463 | 0.450 |
Why?
|
| Cost Savings | 1 | 2019 | 913 | 0.440 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 1264 | 0.390 |
Why?
|
| Data Collection | 1 | 2020 | 3321 | 0.360 |
Why?
|
| Sexual Behavior | 1 | 2020 | 2178 | 0.350 |
Why?
|
| Behavioral Risk Factor Surveillance System | 2 | 2020 | 208 | 0.320 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 1998 | 0.320 |
Why?
|
| Insurance Coverage | 1 | 2020 | 1934 | 0.310 |
Why?
|
| Skin | 2 | 2020 | 4474 | 0.300 |
Why?
|
| Medicaid | 1 | 2020 | 2810 | 0.270 |
Why?
|
| Fund Raising | 1 | 2022 | 49 | 0.200 |
Why?
|
| Prevalence | 5 | 2020 | 15698 | 0.180 |
Why?
|
| Scleroderma, Localized | 1 | 2020 | 87 | 0.170 |
Why?
|
| Fasciitis | 1 | 2020 | 67 | 0.170 |
Why?
|
| Lupus Erythematosus, Cutaneous | 1 | 2020 | 73 | 0.170 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 7860 | 0.160 |
Why?
|
| Skin Diseases, Infectious | 1 | 2019 | 77 | 0.160 |
Why?
|
| United States | 9 | 2022 | 72202 | 0.150 |
Why?
|
| Dermatomyositis | 1 | 2020 | 259 | 0.140 |
Why?
|
| Scalp | 1 | 2020 | 389 | 0.140 |
Why?
|
| Hospitals, Urban | 1 | 2019 | 500 | 0.140 |
Why?
|
| Patient Advocacy | 1 | 2019 | 360 | 0.140 |
Why?
|
| Eosinophilia | 1 | 2020 | 560 | 0.130 |
Why?
|
| Dermatologic Agents | 1 | 2020 | 311 | 0.130 |
Why?
|
| Hypothermia, Induced | 1 | 2020 | 756 | 0.120 |
Why?
|
| Ultraviolet Rays | 1 | 2020 | 1079 | 0.120 |
Why?
|
| Conflict of Interest | 1 | 2019 | 554 | 0.110 |
Why?
|
| Female | 15 | 2022 | 391875 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 12969 | 0.110 |
Why?
|
| Hospital Costs | 1 | 2019 | 948 | 0.110 |
Why?
|
| Arthritis | 1 | 2018 | 682 | 0.100 |
Why?
|
| Drug Industry | 1 | 2019 | 788 | 0.100 |
Why?
|
| Cross-Sectional Studies | 4 | 2020 | 26063 | 0.100 |
Why?
|
| Male | 11 | 2022 | 360035 | 0.090 |
Why?
|
| Humans | 18 | 2022 | 760437 | 0.090 |
Why?
|
| Testosterone | 1 | 2020 | 2471 | 0.080 |
Why?
|
| Dermatology | 1 | 2019 | 916 | 0.080 |
Why?
|
| Self Report | 1 | 2020 | 3721 | 0.080 |
Why?
|
| Retrospective Studies | 6 | 2022 | 80430 | 0.070 |
Why?
|
| Health Personnel | 1 | 2020 | 3331 | 0.070 |
Why?
|
| Mental Health | 1 | 2020 | 3241 | 0.070 |
Why?
|
| Sex Factors | 1 | 2020 | 10538 | 0.060 |
Why?
|
| Length of Stay | 1 | 2019 | 6413 | 0.060 |
Why?
|
| Middle Aged | 6 | 2020 | 220382 | 0.060 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 20985 | 0.060 |
Why?
|
| Melanoma | 1 | 2022 | 5704 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 5662 | 0.050 |
Why?
|
| Neoplasms | 3 | 2020 | 22083 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 15257 | 0.050 |
Why?
|
| Medicare | 1 | 2020 | 6732 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 15820 | 0.050 |
Why?
|
| Mental Disorders | 1 | 2020 | 6831 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2022 | 41366 | 0.040 |
Why?
|
| Privacy | 1 | 2022 | 233 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 11729 | 0.040 |
Why?
|
| Risk Factors | 3 | 2022 | 74055 | 0.040 |
Why?
|
| Antibodies, Antinuclear | 1 | 2020 | 344 | 0.040 |
Why?
|
| Case-Control Studies | 3 | 2022 | 22097 | 0.040 |
Why?
|
| Adult | 4 | 2020 | 220781 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 13616 | 0.040 |
Why?
|
| Time Factors | 1 | 2019 | 39947 | 0.040 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2019 | 487 | 0.030 |
Why?
|
| Patient Care | 1 | 2020 | 621 | 0.030 |
Why?
|
| Aged | 3 | 2022 | 168840 | 0.030 |
Why?
|
| Mastectomy | 1 | 2022 | 1822 | 0.030 |
Why?
|
| Disclosure | 1 | 2019 | 748 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 1663 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2019 | 7948 | 0.010 |
Why?
|
| Prognosis | 1 | 2020 | 29551 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 39078 | 0.010 |
Why?
|
| Pregnancy | 1 | 2020 | 29831 | 0.010 |
Why?
|
| Young Adult | 1 | 2019 | 59068 | 0.010 |
Why?
|
| Child | 1 | 2019 | 80086 | 0.010 |
Why?
|
| Adolescent | 1 | 2019 | 88196 | 0.010 |
Why?
|